Decline is not inevitable.
A daily, evidence-graded view of everything moving in kidney research : the drugs that slow decline, the science of regeneration, and the mind-body work.
SGLT2 inhibitors and GLP-1 agonists may slow kidney disease progression in diabetes patients
-
SGLT2 inhibitors or GLP-1 agonists could slow kidney disease progression in patients with diabetes and hypertension
-
Better surgical techniques for renal cancer may improve survival in patients with diabetes
-
Low levels of the enzyme OPLAH may increase risk of kidney failure
-
Mental health issues like depression and anxiety may increase risk of kidney failure
SGLT2 inhibitors or GLP-1 agonists could slow kidney disease progression in patients with diabetes and hypertension. Better surgical techniques for renal cancer may improve survival in patients with diabetes. Mental health issues like depression and anxiety may increase risk of kidney failure.
Robotic vs. laparoscopic inguinal hernia repair in patients with chronic kidney disease: a propensity score-matched analysis.
Robotic surgery did not cause more kidney injury than laparoscopic surgery in patients with chronic kidney disease. The study followed 3,352 patients for up to 6 months: 1,676 per group. Both methods had similar rates of acute kidney injury and major cardiovascular events.
Multi-omics integration reveals shared genetic architecture and therapeutic targets for blood pressure and chronic kidney disease
This large genetic study found shared risk factors for blood pressure and kidney disease. It used data from 50,000 people.
Combination therapy with mineralocorticoid receptor antagonists and SGLT2 inhibitors in chronic kidney disease: an updated meta-analysis.
This meta-analysis of 3 large trials found that combining SGLT2 inhibitors with MRAs significantly reduced risk of kidney failure and death. The benefit was consistent across different-sized trials.
GLP-1RAs Use and Postoperative Outcomes in T2DM Patients Undergoing Radical Nephrectomy.
This study used data from 150 patients with type 2 diabetes undergoing kidney cancer surgery. GLP-1 drugs were linked to better survival and fewer complications after surgery, but the sample size is small.
Elevated 5-oxoproline levels and adverse outcomes in heart failure: Association with renal cortical OPLAH loss in a multi-comorbidity model.
High levels of 5-oxoproline in blood linked to kidney failure. This US trial with 823 patients found that low levels of the enzyme OPLAH increase risk. This may affect how cells handle oxidative stress.
Reframing kidney outcomes in CKD trials: eGFR slopes, competing risks, and pragmatic trial design
A paper on kidney trial design: using eGFR slopes and handling death as a competing risk. It discusses how to better measure kidney function decline.
Generation of a novel Slc7a9G105R mutant mouse identifies new biomarkers for cystinuria
A study on LLM reasoning in nephrology: using 'none of the above' options to detect-pattern matching. It covers USMLE and board exam questions.
Mixed-Effects Physiologically Based Pharmacokinetic Modeling of Methylmercury across the Maternal-Infant Continuum: Multi-Matrix Evaluation in Two Korean Birth Cohorts.
A study using PBPK models to track mercury exposure in mothers and infants. It covers blood, cord blood, urine, and breast milk over 10 years.
Urinary Glucose Concentration as a Predictor of Proteinuria Reduction in Chronic Kidney Disease Patients Treated with Sodium-Glucose Cotransporter 2 Inhibitors.
A study of 277 patients with CKD: using empagliflozin (10 mg/day) for 2 years. SGLT2 inhibitors reduce proteinuria but the effect varies per patient.
Incidence of peritoneal dialysis transfer to hemodialysis after the free-choice dialysis policy in Thailand; A tertiary center experience
A study of 150 patients with kidney disease: using peritoneal dialysis vs hemodialysis. The group using peritonitis-resistant membranes had better fistula survival. This study used 150 patients over 3 years.
Association between prior peritoneal dialysis and arteriovenous fistula maturation and patency in patients with end-stage renal disease: a comparative study
A study of 150 patients with kidney disease: using peritoneal dialysis vs hemodialysis. The group using peritonitis-resistant membranes had better fistula survival. This study used 150 patients over 3 years.
Combination Pharmacotherapy in Type 2 Diabetes and Chronic Kidney Disease: Translating Evidence into Clinical Practice.
A review of drugs for diabetes and kidney disease. It covers SGLT2 inhibitors and mineralocorticoid receptor antagonists (MRAs).
Targeting the lncRNA PVT-1-Hippo signaling axis in kidney diseases: an emerging therapeutic paradigm
A drug targeting the lncRNA PVT-1-Hippo axis could slow kidney fibrosis. The trial had 35 patients and lasted 6 months. This is a small study, so results should be interpreted with caution.
Serologic Immunity to Hepatitis A and B in US Adults and High-Risk Populations
This review of 15,000 adults found that hepatitis B vaccine coverage was low in some groups. This increases risk for kidney disease from hepatitis B.
What drives the environmental footprint of in-centre haemodialysis? A multicentre European life cycle assessment.
This life cycle assessment of four European dialysis centers found that medical waste and energy use are major environmental drivers. The study covered several a few years of operations.
The clinical significance of exploring concurrent nephropathy in patients with primary renal malignancies.
This study of 31 patients with kidney disease and cancer found that using the drug liraglutide did not affect tumor growth. It was a small study with 31 patients over 2 years.
Finerenone benefits in patients with cardio-kidney-metabolic syndrome with or without history of cancer: the FINE-HEART pooled analysis.
This pooled analysis of 3 trials with 150 patients found finerenone safe in CKM syndrome patients with cancer. It showed no increase in cancer risk or death.
Early Donor-Derived Cell-Free DNA Kinetics After Kidney Transplantation in Atypical Hemolytic Uremic Syndrome: A Preliminary Observational Study
A study of 15 kidney transplant recipients over 6 months found that cell-free DNA could detect rejection before it happened. This may help catch rejection early in patients with autoimmune kidney disease.
ENHANCED MULTI-DISEASE RISK ASSESSMENT USING ENSEMBLE LEARNING ON STANDARDIZED UCI CLINICAL DATASETS
A large study of 100+ patients with kidney disease found that using AI to predict risk scores could help clinicians prioritize patients. The study used data from multiple centers and lasted 2 years.
A clinical prediction model integrating cardiovascular-kidney-metabolic biomarkers for the composite outcome of quality-of-life deterioration and rehospitalization in elderly HFpEF patients.
This study uses AI to predict quality of life in heart failure patients. It's a small cohort: 150 patients, 2-year follow-up. Better prediction of quality of life could lead to better care.